A 62-year-old man from Delhi presents with a 2-year history of progressive tremor at rest, rigidity, and bradykinesia. Neurological examination confirms pill-rolling tremor and cogwheel rigidity. Brain MRI is normal. Based on the clinical presentation suggesting Parkinson disease with presumed nigrostriatal dopaminergic degeneration, what is the most appropriate next step in management?

Explanation

## Clinical Context: Early Parkinson Disease Management The patient presents with classic cardinal features of Parkinson disease: resting tremor (pill-rolling), cogwheel rigidity, and bradykinesia over 2 years. MRI exclusion of secondary causes confirms a primary neurodegenerative process affecting the nigrostriatal dopaminergic pathway. ## Basal Ganglia Circuit Pathophysiology **Key Point:** In Parkinson disease, degeneration of dopaminergic neurons in the substantia nigra pars compacta disrupts the direct (facilitatory) and indirect (inhibitory) pathways of the basal ganglia. Loss of dopamine leads to relative hyperactivity of the indirect pathway, resulting in excessive inhibition of thalamic output and the motor symptoms observed. ## Why Levodopa-Carbidopa is the Most Appropriate Next Step **High-Yield:** Levodopa-carbidopa remains the gold standard and most effective symptomatic treatment for Parkinson disease across all age groups. Current guidelines (MDS, AAN, and updated Indian neurology consensus) support levodopa as first-line therapy because: 1. **Superior efficacy**: Levodopa provides the greatest degree of motor symptom control compared to any other agent. 2. **Functional impairment**: A 2-year history of progressive tremor, rigidity, and bradykinesia indicates functionally significant disease warranting the most effective available therapy. 3. **Revised safety perspective**: Long-term studies (ELLDOPA trial and subsequent data) indicate that early levodopa initiation does not accelerate disease progression; dyskinesia risk is related to disease severity and duration, not levodopa exposure alone. 4. **Carbidopa component**: Inhibits peripheral dopa-decarboxylase, reducing systemic side effects and allowing lower levodopa doses. ## Why Not the Other Options? | Option | Rationale for Deferral | |--------|------------------------| | **Dopamine agonist monotherapy (ropinirole)** | Previously preferred in younger patients to delay levodopa, but current evidence shows inferior symptom control and significant side effects (impulse control disorders, somnolence, hallucinations). No longer considered superior first-line per updated guidelines. | | **PET with 18F-DOPA** | Not routine for diagnosis. Clinical diagnosis is sufficient; PET is reserved for atypical presentations or diagnostic uncertainty (e.g., distinguishing PD from essential tremor or atypical parkinsonism). | | **DBS surgery** | Not first-line. Indicated only after 5+ years of disease with motor complications (dyskinesia, fluctuations) refractory to optimized medical management. | **Clinical Pearl:** The shift away from dopamine agonist monotherapy as the default first-line reflects updated understanding: levodopa's superior efficacy and an improved safety profile when used appropriately outweigh the theoretical benefit of "saving" levodopa for later. This is consistent with Harrison's Principles of Internal Medicine (21st ed.) and current MDS Practice Recommendations.